U.S. Bacterial Conjunctivitis Drugs Market to be Restricted by Patent Expirations


  • Published On : Jul 27, 2015
The overall demand for antibacterial drugs in the U.S. is on the rise owing to the rising incidence of ophthalmic bacterial infections. According to a 2013 clinical study by the American Medical Association, more than 50% of the total number of cases of conjunctivitis in the U.S. were caused due to bacterial infections. In a recently conducted study, in a sample of 10,000, the total number of conjunctivitis cases were 135. This makes it evident that there is high incidence of bacterial conjunctivitis in the U.S., which in turn boosts the demand for bacterial conjunctivitis drugs. 

The U.S. bacterial conjunctivitis drugs market is anticipated to expand at a 2.7% CAGR between 2012 and 2018 and contract at a negative growth rate of -3.73% between 2018 and 2024. The effect of these positive and negative rates of growth will effectively reduce the value of this market from US$473.3 million in 2013 to US$439.8 million by 2024.

Fluoroquinolones: An Extensively Prescribed Class of Drugs

The bacterial conjunctivitis drugs market is segmented on the basis of drug classes. Some of the bacterial strains that cause bacterial conjunctivitis are gonococci, chlamydial, staphylococci, and streptococci organisms. Most bacterial conjunctivitis cases are generally acute and self-limited. Macrolides, aminoglycosides, and fluoroquinolones are some of the main antibacterial drugs that dominate the U.S. bacterial conjunctivitis drugs market. Other types of drugs are fusidic acid, polymyxin, doxycycline, and bacitracin. Owing to their high efficacy against bacterial strains, fluoroquinolones are by far the most widely prescribes class of drugs in the U.S. bacterial conjunctivitis drugs market. 

It has been observed that people of all age groups are prone to bacterial conjunctivitis, be it neonates, children, adults, and geriatrics. Increasing prevalence of bacterial conjunctivitis all across the U.S. is a pivotal factor that drives the bacterial conjunctivitis drugs market in this region. 

Blockbuster Drugs to Hinder Market Growth

The prominent companies operating in the U.S. bacterial conjunctivitis drugs market are Valeant Pharmaceuticals International Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Perrigo Company plc, Novartis AG, Merck & Co. Inc., F. Hoffman-La Roche Ltd., Bayer AG, Akorn Inc., and Actavis plc. Most pharmaceutical companies in the U.S. bacterial conjunctivitis drugs market lay emphasis on the commercialization of antibacterial drugs. The new market entrants also focus on this aspect in order to gain a fair share in the U.S. market. 

The market for fluoroquinolones is expected to witness declining sales in the forthcoming years. The introduction of blockbuster medications such as Besivance, Moxeza, Vigamox, and Zymaxid has had a negative impact on the performance of the U.S. bacterial conjunctivitis drugs market and this will gradually lead to the negative rate of growth of this market in the forecast period. 

The U.S. bacterial conjunctivitis drugs market will also witness the patent expiries of these popular formulations, which will have an adverse impact on the performance of this market. Another market restraint is the rising trend of genericization of several antibacterial drugs, which leads to the development of a highly unprofitable and a crowded market. 

New market participants in the U.S. bacterial conjunctivitis drugs market should mainly focus on developing combination drug products and should also implement product development partnership business models.

Browse Full U.S. Bacterial Conjunctivitis Drugs Market Research Report With Complete TOC @ http://www.persistencemarketresearch.com/market-research/u.s-bacterial-conjunctivitis-drugs-market.asp
Back To Top